2 Overvalued Biotech Stocks Still Worth Buying

If you're like many investors, the answer is "yes" -- but if you aren't careful, being fixated on a high P/S ratio can lead you to miss out on some of the best growth stock opportunities. NexoBrid has already been proven safe and effective in phase 3 clinical trials, so it's approaching the final steps before obtaining regulatory approval in the U.S. It's already been authorized in the EU.